You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (3) |
Back to Search
Evaluation of the safety and efficacy of m-beam and m-beac regimen for autologous hematopoietic stem-cell transplantation pretreatment due to the shortage supply of melphalan (the second report)
- In: Poster presentation
- At: Seoul (South Korea) (2017)
- Type: Poster
- Poster code: POS-HPS-093
- By: MIYAGAWA, Keiko (Kameda Medical Center, Kamogawa, Chiba, Japan)
- Co-author(s): Keiko Miyagawa: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
Yusuke Nakagawa: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
Tatsuya Isezaki: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
Koji Masuda: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
Osamu Yasumuro: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
Kosei Matsue: Department of Hematology, Kameda Medical Center, Chiba, Japan
Ryokan Funakoshi: Department of Pharmacy, Kameda Medical Center, Chiba, Japan - Abstract:
Background
Melphalan IV (Mel) distribution has been suspended globally due to manufacturing process difficulties occurring in November 2015. We have been using the combination of Ranimustine/Etoposide/Cytarabine/Cyclophosphamide (M-BEAC) as pretreatment for autologous stem-cell transplantation (ASCT) instead of.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026